23 Oct Singapore’s HTA decisions in Prismaccess and Evalumade
Considered to be one of the best health-care systems in the world, Singapore is a model of quality, efficiency and affordability. Singapore provides universal health care coverage to its citizens and is funded through a combination of general tax revenue, multi-layered health care financing schemes and private individual savings.
Singapore’s Agency for Care Effectiveness (ACE) has started publishing HTA drug guidance reports as of May 2017. The ACE is the health technology assessment agency within Singapore’s Ministry of Health and was established in 2015 to improve decision-making by providing information on clinical and cost-effectiveness. The reports produced by the ACE aim to improve transparency regarding the use of technologies, subsidy decisions as well as clinical and economic evidence.
For more information, please don’t hesitate to contact us or refer to the ACE website: